Skip to main content

Publications

A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis.

Lin C, Patel AA, Huo D, Karrison T, van Besien K, Godwin J, Sher D, Weiner H, Green M, Wade JL, Klisovic R, Baer MR, Larson RA, Stock W, Odenike O

A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 Nov 26; 8(22):5735-5743.

PMID: 39250708

Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach.

Zhao F, Polley E, McClellan J, Howard F, Olopade OI, Huo D

Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach. Breast Cancer Res. 2024 Oct 29; 26(1):148.

PMID: 39472970

Anticipation in families with MLH1-associated Lynch syndrome.

Pandey AS, Drogan C, Huo D, Postula K, Garg SM, Kupfer SS

Anticipation in families with MLH1-associated Lynch syndrome. Cancer. 2024 Oct 22.

PMID: 39435727

ASO Author Reflections: Breast-Conserving Surgery After Neoadjuvant Systemic Therapy for Early-Stage Breast Cancer: Quantitative Biomarkers and Disparities in the Precision-Medicine Era.

Freeman JQ, Huo D, Howard FM

ASO Author Reflections: Breast-Conserving Surgery After Neoadjuvant Systemic Therapy for Early-Stage Breast Cancer: Quantitative Biomarkers and Disparities in the Precision-Medicine Era. Ann Surg Oncol. 2024 Dec; 31(13):8904-8905.

PMID: 39313726

Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer.

Freeman JQ, Shubeck SP, Chen N, Yarlagadda SR, Nanda R, Huo D, Howard FM

Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer. Ann Surg Oncol. 2024 Dec; 31(13):8829-8842.

PMID: 39251516

Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants That Confer Risk for Breast Cancer.

Sun X, Verma SP, Jia G, Wang X, Ping J, Guo X, Shu XO, Chen J, Derkach A, Cai Q, Liang X, Long J, Offit K, Oh JH, Reiner AS, Watt GP, Woods M, Yang Y, Ambrosone CB, Ambs S, Chen Y, Concannon P, Garcia-Closas M, Gu J, Haiman CA, Hu JJ, Huo D, John EM, Knight JA, Li CI, Lynch CF, Mellemkjær L, Nathanson KL, Nemesure B, Olopade OI, Olshan AF, Pal T, Palmer JR, Press MF, Sanderson M, Sandler DP, Troester MA, Zheng W, Bernstein JL, Buas MF, Shu X

Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants That Confer Risk for Breast Cancer. Cancer Res. 2024 Aug 01; 84(15):2533-2548.

PMID: 38832928

Benign and Malignant Outcomes in the Offspring of Females Exposed In Utero to Diethylstilbestrol (DES): An Update from the NCI Third Generation Study.

Titus L, Hatch EE, Bertrand KA, Palmer JR, Strohsnitter WC, Huo D, Curry M, Hyer M, Aagaard K, Gierach GL, Troisi R

Benign and Malignant Outcomes in the Offspring of Females Exposed In Utero to Diethylstilbestrol (DES): An Update from the NCI Third Generation Study. Cancers (Basel). 2024 Jul 18; 16(14).

PMID: 39061214

Assessing the Relationship Between Neighborhood Socioeconomic Disadvantage and Telemedicine Use Among Patients With Breast Cancer and Examining Differential Provisions of Oncology Services Between Telehealth and In-Person Visits: Quantitative Study.

Freeman JQ, Zhao F, Howard FM, Nanda R, Olopade OI, Huo D

Assessing the Relationship Between Neighborhood Socioeconomic Disadvantage and Telemedicine Use Among Patients With Breast Cancer and Examining Differential Provisions of Oncology Services Between Telehealth and In-Person Visits: Quantitative Study. JMIR Cancer. 2024 Jul 18; 10:e55438.

PMID: 39024570

Expenditures and Use of Hypofractionated Radiation Therapy Treating Breast Cancer Among Medicare Advantage Enrollees, 2009 to 2017.

Saulsberry L, Liao C, Huo D

Expenditures and Use of Hypofractionated Radiation Therapy Treating Breast Cancer Among Medicare Advantage Enrollees, 2009 to 2017. Adv Radiat Oncol. 2024 Sep; 9(9):101568.

PMID: 39176100

Multi-tissue transcriptome-wide association studies identified 235 genes for intrinsic subtypes of breast cancer.

Li JL, McClellan JC, Zhang H, Gao G, Huo D

Multi-tissue transcriptome-wide association studies identified 235 genes for intrinsic subtypes of breast cancer. J Natl Cancer Inst. 2024 Jul 01; 116(7):1105-1115.

PMID: 38400758